Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SYK
REST API REST API
Homo sapiens
SYK is differentially expressed in 294 experiments: 131 organism parts: thymus, liver, ... (129 more);, 250 disease states: normal, acute myeloid leukemia, ... (248 more);, 129 cell types 485 cell lines 40 compound treatments and 77 other conditions.
Orthologs SYK (Gallus gallus)   syk (Danio rerio)   Sykb (Mus musculus)   Q32PK0_BOVIN (Bos taurus)   hop (Drosophila melanogaster)   Syk (Rattus norvegicus)   syk (Xenopus laevis)   Q6JDG6_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, leukotriene biosynthetic process, protein binding, cytoplasm, cell proliferation, intracellular, peptidyl-tyrosine phosphorylation, protein tyrosine kinase activity, blood coagulation, protein domain specific binding, protein complex assembly, integrin-mediated signaling pathway, activation of MAPK activity, ATP binding, activation of JUN kinase activity, cell surface receptor linked signaling pathway, protein kinase binding, nucleotide binding, protein serine/threonine kinase activity, integrin binding, non-membrane spanning protein tyrosine kinase activity, organ morphogenesis, protein kinase activity, regulation of immune response, positive regulation of alpha-beta T cell proliferation, positive regulation of B cell differentiation, B cell receptor complex, receptor signaling protein tyrosine kinase activity, positive regulation of interleukin-3 biosynthetic process, B cell receptor signaling pathway, positive regulation of peptidyl-tyrosine phosphorylation, positive regulation of granulocyte macrophage colony-stimulating factor biosynthetic process, positive regulation of alpha-beta T cell differentiation, positive regulation of gamma-delta T cell differentiation, positive regulation of calcium-mediated signaling, interspecies interaction between organisms, beta selection, serotonin secretion, positive regulation of mast cell degranulation, leukocyte cell-cell adhesion, enzyme linked receptor protein signaling pathway, neutrophil chemotaxis, T cell receptor complex, platelet activation, protein autophosphorylation, protein phosphorylation, intracellular signal transduction
InterPro Term SH2, Prot_kinase_cat_dom, Tyr_kinase_non-rcpt_SYK/ZAP70, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession P43405
Search EB-eye ENSG00000165025
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (37 experiments)

Factor Value U/D Experiments
SW480
4
E-MTAB-37, E-MEXP-1014, E-GEOD-2509, E-GEOD-18005
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823
A549
2
E-GEOD-3202, E-GEOD-6013
AGS
2
E-GEOD-15460, E-MTAB-37
MDA468
2
E-MEXP-440, E-MTAB-62
479 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-TABM-34, ... (59 experiments)

Factor Value U/D Experiments
CD8+ T cell
1
4
E-AFMX-5, E-TABM-145, E-MTAB-25, E-GEOD-6740, E-GEOD-19069 ... (5 experiments)
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3204, E-GEOD-3920
123 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MTAB-62, E-MTAB-680, E-GEOD-5418, ... (63 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-37, E-GEOD-3726, E-MTAB-57
glioblastoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-4290
mesothelioma
2
E-MTAB-37, E-MTAB-62
osteosarcoma
2
E-MTAB-37, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
cervical carcinoma
2
E-MTAB-62, E-GEOD-5823
244 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-7400, E-TABM-782, E-GEOD-5824, E-TABM-868, ... (31 experiments)

Factor Value U/D Experiments
control
2
E-GEOD-3284, E-GEOD-4006
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
none
6
7
E-TABM-782, E-MEXP-1958, E-MEXP-1230, E-GEOD-2649, E-MEXP-1601, ... (13 experiments)
vanadium pentoxide
1
E-GEOD-5339
HMB-PP (phosphoantigen)
1
1
E-MEXP-1601
valproic acid
1
E-GEOD-1615
34 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-1563, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-MEXP-958, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-2509, E-GEOD-22148, E-TABM-147, E-GEOD-19665, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-MEXP-1996, E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-MEXP-421, ... (12 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-TABM-127, E-GEOD-20540, E-MEXP-1446, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-MEXP-1648, ... (32 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-980, E-GEOD-17400, ... (6 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-GEOD-7540, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-1460, E-GEOD-17636, E-GEOD-7114, E-MEXP-1403 ... (5 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19246

Replicate
studied in E-GEOD-18791, E-GEOD-10896, E-GEOD-17204

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-GEOD-3485 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-1643, E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541, E-GEOD-4922

Processing time: 0.489 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM